Back

Clinical characteristics and outcomes of super-low-dose edoxaban 15 mg compared with reduced dose 30 mg for high-bleeding-risk patients with venous thromboembolism: from the COMMAND VTE Registry-2

28 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Venous thromboembolism Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Daisuke Baba

Otsu Red Cross, Otsu, Shiga (Japan)

7 More presentations in this session

Presentation thumbnail
Genetically mediated differences in LDL cholesterol were not consistently associated with venous thromboembolism: rare variant analyses in over 700,000 participants
Doctor S. Kany (Hamburg, DE)
Abstract Slides
Presentation thumbnail
Diagnostic yield of ultrasound and rule-out accuracy of D-dimer in fast-track diagnostic strategies for deep venous thrombosis
Mr J. Madsen (DK)
Abstract Slides
Presentation thumbnail
Ischemic heart disease vs. venous thromboembolism: a nationwide mortality trend analysis (1999–2020)
Doctor S. Waqas (Royal Oak, US)
Abstract Slides
Presentation thumbnail
Effectiveness of high-dose versus standard-dose influenza vaccine against venous thromboembolic events: a post hoc analysis of the DANFLU-2-2 trial
Doctor K. Kader (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Missed opportunities: lower rehabilitation offers to women after pulmonary embolism
Miss A. Kronsell (DK)
Abstract Slides

Access the full session

Session thumbnail
Venous thromboembolism

The Event

Event poster

ESC Congress 2026

28 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Low-dose edoxaban in patients 80 years and older with atrial fibrillation and dose-reduction criteria: randomized analysis between edoxaban 15 mg and 30 mg
1 September 2025
thumbnail
Congress Presentation
Risk factors of recurrence in patients with cancer-associated venous thromboembolism: from the COMMAND VTE Registry
28 August 2021
thumbnail
Congress Presentation
Effectiveness and safety of half-dose thrombolysis in intermediate-high risk pulmonary embolism: a single centre experience
9 March 2024
thumbnail
Congress Presentation
Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2
28 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources